Abstract 5490
Background
This analysis described the population pharmacokinetics (popPK) of TALA in cancer patients to identify significant covariates, evaluate the PK comparability of 4 x 0.25 mg capsules and 1 x 1 mg capsule as a 1 mg dose, and provide individual PK predictions for PK/pharmacodynamic analysis.
Methods
The data used for the analysis included 6207 PK observations from 490 patients treated with TALA in 4 studies (PRP-001, PRP-002, ABRAZO, and EMBRACA); the detailed PK data will be disclosed in the poster. TALA concentration-time data were analyzed by using a nonlinear mixed-effects modeling approach with NONMEM. Inclusion of covariates was conducted by visual inspection of ETAs vs covariates of interest followed by statistical test (stepwise covariate modeling).
Results
A 2-compartment model with 1st-order absorption best described the PK of TALA. The estimated population-typical value for apparent oral clearance (CL/F) was 6.37 L/h, apparent volume of central compartment (V2/F) 162 L, and absorption rate constant (ka) 1.22 1/hour. While food and formulation were significant covariates on ka, they had no impact on bioavailability (F). Coadministration with strong P-gp inhibitors increased the relative bioavailability by 44.7%. Baseline creatinine clearance was significant for CL/F with a 14.4% and 37.1% decrease in CL/F for patients with mild and moderate renal impairment, respectively. Asian (23.7% higher CL/F), age (on CL/F), and baseline body weight (BWT) (on V2/F) are significant covariates but not considered clinically relevant. Other covariates tested (sex, liver enzymes, acid-reducing agents) were not significant on relevant PK parameters.
Conclusions
The population PK model adequately described the observed PK data of TALA. Results suggest that no dose adjustment is necessary based on a patient’s age, BWT, race, or sex or for patients with mild renal or hepatic impairment or for patients taking acid-reducing agents. TALA can be taken without regard of food. The PK of 1 x 1 mg capsule and 4 x 0.25 mg capsules as 1 mg dose was comparable. The dose of TALA should be reduced to 0.75 mg for patients taking strong P-gp inhibitors or for patients with moderate renal impairment.
Clinical trial identification
NCT01945775, NCT02034916, NCT01286987, NCT01399840.
Legal entity responsible for the study
Pfizer, Inc.
Funding
Pfizer, Inc.
Editorial Acknowledgement
Editorial and medical writing support funded by Pfizer Inc. were provided by Edwin Thrower, PhD, Mary Kacillas and Paula Stuckart of Ashfield Healthcare Communications, Middletown, Connecticut.
Disclosure
Y. Yu, C. Durairaj, H. Shi, D.D. Wang: Employee: Pfizer, Inc.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract